Compare Citius Pharmaceuticals Inc (CTXR) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Teucrium Wheat Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Teucrium Wheat Fund trades at $24.41 (market cap $273.67M). The key difference: Teucrium Wheat Fund is far larger — about 20.1× Citius Pharmaceuticals Inc's market cap, and Teucrium Wheat Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Teucrium Wheat Fund for 40 Days on average.
| CTXR | WEAT | |
|---|---|---|
Market Cap | $13.62M | $273.67M |
Volume | 132,438 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.82 | $28.00 |
52-Week Low | $0.48 | $19.88 |
Typical Hold Time | 17 Days | 40 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
WEAT is trading at $24.41, down 1.97% with a bearish technical outlook as moving averages signal selling pressure. The wheat ETF faces mixed sentiment with recent price gains of 9.9% over the past month but current technical indicators showing weakness. Key support sits at $24 with resistance at $25, creating a tight trading range.
The ETF's performance remains tied to agricultural commodity volatility and inflation trends. Recent inflation data shows prices above Fed targets, potentially supporting commodity investments. However, technical weakness and the question of whether the recent rally is overdone present near-term challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
